Study Overview

The study examined MSC infusion in participants with confirmed ASD diagnoses, evaluating both behavioral outcomes and EEG (electroencephalogram) metrics before and after treatment. Participants included children, adolescents, and adults with confirmed ASD diagnoses.

How MSCs May Help in Autism

Understanding how MSC therapy may benefit children with autism requires looking beyond behavior alone. Autism is increasingly understood as a whole-body condition with significant biological components.

Key Findings: Consistent Neurological & Clinical Improvement

What Is Stem Cell Therapy for Autism?

"Stem cell therapy for autism" usually refers to the infusion of mesenchymal stem/stromal cells (MSCs) into a child or adult with autism spectrum disorder (ASD), with the stated goal of influencing biological processes — most often neuroinflammation — that some researchers hypothesize contribute to certain autism presentations.

MSCs are cells that can be isolated from several tissue sources, including umbilical cord tissue, bone marrow, and adipose (fat) tissue. Most current research and most U.S. clinical access programs use donor (allogeneic) umbilical-cord-derived MSCs rather than a patient's own cells.

It's important to be precise about what this treatment is and is not. It is not a genetic therapy, it does not alter a person's DNA, and it is not positioned in the research literature as a cure for autism. Autism spectrum disorder is a lifelong neurodevelopmental difference, and BetterStem does not frame it as a condition that must be eliminated — the stated goal of MSC research in this space is to explore whether cell therapy may support certain aspects of daily functioning or quality of life, not to change who a person is.

Because "stem cell therapy" is sometimes used loosely to describe several different products and delivery methods — MSCs, cord blood mononuclear cells, exosomes, different infusion routes — this guide uses precise terminology throughout.

MSCs vs. Exosomes — Two Different Things Often Confused

MSCs are living cells. Exosomes (a type of extracellular vesicle) are tiny particles that cells — including MSCs — release; they carry proteins, lipids, and genetic material that may influence nearby cells, but they are not cells themselves and cannot divide or engraft.

Some clinics market exosome products for autism based on the idea that they might deliver the same signaling benefits as MSCs without using live cells. As of this writing, there is no completed, published human clinical trial evidence for exosome therapy in autism — only early-stage, unpublished trial registrations and preclinical animal research.

What the Evidence Shows

What Is Still Unknown

• Why the largest controlled trial (Duke IMPACT) did not replicate the more promising signals seen in smaller, uncontrolled earlier studies.
• Whether any particular cell dose, source, or administration route is more effective than another — no study has directly compared these variables in autism.
• Which children, if any, are more likely to respond, and by what measurable mechanism.
• Whether findings from one specific cell product can be generalized to a different clinic's product.
• Whether exosome therapy provides any measurable clinical benefit for autism in humans.

Is It FDA-Approved? Understanding the Regulatory Picture

No stem cell or exosome product is FDA-approved for autism spectrum disorder. The FDA has approved only one narrow category of stem cell product for any use — cord-blood-derived hematopoietic stem cells for certain blood-forming disorders — and that approval has nothing to do with autism.

The FDA has issued public consumer alerts specifically warning that regenerative medicine products, including stem cells and exosomes, offered for autism and many other unapproved uses have not been evaluated by the agency for safety or effectiveness.

Is It Safe? A Realistic Look at Risks

Published safety studies of MSC infusion in children with autism have generally reported mild, self-limited side effects (such as infusion-related reactions, low-grade fever, or transient irritability) and no serious treatment-related adverse events within their study populations — but these studies are small, and safety data cannot be assumed to apply to every product, dose, or provider.

What Happens During Treatment

While specific protocols vary by provider, MSC therapy for autism is generally administered as one or more intravenous (IV) infusions in an outpatient setting, preceded by a candidate-evaluation process (medical history review, and in some programs, laboratory or biomarker testing) to assess eligibility. The infusion itself typically takes under an hour, followed by a monitoring period.

What Results Can Families Realistically Expect?

This is one of the most important questions a family can ask, and it deserves an honest answer: results are not guaranteed, and current controlled research — including the largest trial to date — has not established that MSC therapy reliably produces measurable improvement in core autism symptoms.

Some families report positive observations after treatment; these parent-reported experiences are real to the families who share them, but they are not the same as clinical trial evidence, and they cannot be generalized to predict what another child will experience. Some children may show no noticeable change.

How to Evaluate a Stem Cell Program

Because this field includes both careful, transparent providers and less scrupulous ones, independent organizations such as the International Society for Stem Cell Research (ISSCR) publish frameworks for evaluating any regenerative medicine program before enrolling. At minimum, families should be able to get clear answers about:

How Regenerative Treatment Fits With ABA, Speech, and Occupational Therapy

Regenerative treatment, if a family chooses to pursue it, should not be viewed as a replacement for established, evidence-based autism support — including Applied Behavior Analysis (ABA), speech-language therapy, occupational therapy, or special education services. These interventions have a substantially larger and more mature evidence base than regenerative cell therapy, and stopping them in favor of an investigational treatment is not something this guide, or BetterStem, recommends.

Frequently Asked Questions

The Short Answer

No stem cell product is FDA-approved to treat autism spectrum disorder, and no exosome product is FDA-approved for any use. This is true across the industry, not specific to any one clinic. The FDA has approved only a narrow category of stem cell products overall — primarily cord-blood-derived hematopoietic stem cells used for certain blood and immune system disorders — and that approval has no connection to autism treatment.

What 'FDA-Approved' Actually Means

FDA approval means a manufacturer has submitted evidence from adequate, well-controlled clinical trials demonstrating that a specific product is safe and effective for a specific use, and the FDA has reviewed that evidence and authorized the product to be marketed for that use. This is a rigorous, multi-phase process. For a cell or biologic product, it typically requires completing Phase 1 (safety), Phase 2 (early efficacy signal), and Phase 3 (large-scale efficacy confirmation) trials before a Biologics License Application can be approved.

What 'FDA-Regulated' Means (and Why It's Not the Same Thing)

Human cells and tissue products are regulated by the FDA under a framework known as 21 CFR Part 1271, which governs how such products must be donated, processed, screened, and labeled. A product can be "FDA-regulated" — meaning it falls under this oversight framework, and the facility processing it may need to register with the FDA — without having gone through the separate approval process that establishes its safety and effectiveness for a specific medical use.

What the FDA Has Actually Said

The FDA has published several consumer-facing documents specifically addressing this space:

If It's Not Approved, How Is It Legally Offered?

Investigational products can sometimes be legally accessed outside of a completed approval process — most commonly through participation in a registered clinical trial, or through the federal Right to Try Act (2018), which allows access to certain investigational products under specific conditions for patients who qualify.

Neither pathway means the FDA has determined the product is safe or effective; both require the product to be under an active IND and to have completed at least Phase 1 testing.

What the Evidence Shows

• FDA source documents directly and unambiguously state that no stem cell or exosome product is approved for autism.
• The FDA has taken real enforcement action — including warning letters and a 2019 public safety notification documenting adverse events — against companies marketing unapproved stem cell and exosome products.
• Right to Try and similar access pathways have specific, verifiable legal requirements that a family can ask a provider to document.

Questions to Ask a Provider About Regulatory Status

Frequently Asked Questions

Study Overview

The study examined MSC infusion in participants with confirmed ASD diagnoses, evaluating both behavioral outcomes and EEG (electroencephalogram) metrics before and after treatment. Participants included children, adolescents, and adults with confirmed ASD diagnoses.

How MSCs May Help in Autism

Understanding how MSC therapy may benefit children with autism requires looking beyond behavior alone. Autism is increasingly understood as a whole-body condition with significant biological components.

Key Findings: Consistent Neurological & Clinical Improvement

The Short Answer

Right to Try is an access pathway, not a stamp of approval. The federal Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act, signed into law in 2018, allows eligible patients to request certain investigational drugs and biologics directly, without going through the FDA's individual expanded-access request process. It exists to give patients another route to potentially beneficial treatments earlier — but Congress and the FDA both built the law around products that are still under investigation, meaning their safety and effectiveness have not yet been established through the full clinical trial and approval process.

What the Right to Try Act Actually Says

Under the federal law, a patient may be eligible to request an investigational product if they have been diagnosed with a life-threatening disease or condition, have exhausted approved treatment options, and are unable to participate in a relevant clinical trial. A physician must certify the request in writing, and the physician cannot be compensated by the product's manufacturer for doing so.

The investigational product itself must meet separate conditions: it must have completed Phase 1 testing, remain under an active IND application or active clinical trial investigation, and not be subject to a clinical hold by the FDA.

Who and What Qualifies Under Right to Try

What Right to Try Does NOT Establish

This is the part most often misunderstood, and it matters enormously for a family evaluating any Right to Try-accessed treatment:

• Right to Try does not mean the FDA has reviewed and approved the specific treatment.
• Right to Try does not mean safety has been established — only that the product completed Phase 1 testing, which is designed to assess safety in a small group, not to confirm it broadly.
• Right to Try does not mean effectiveness has been established — Phase 1 trials generally are not designed to test whether a treatment works.
• Right to Try creates no obligation for a manufacturer to provide the product, even to an eligible patient.
• The FDA's role under Right to Try is limited — the agency does not review or approve each individual request the way it does under its separate Expanded Access program.

Right to Try vs. a Clinical Trial: What's the Difference?

What the Evidence Shows

• The Right to Try Act's text and the FDA's own official guidance page both explicitly describe the law as an access mechanism, not a safety or efficacy determination.
• Most U.S. states have enacted their own right-to-try statutes; at least 41 states had done so as of recent tracking, though state laws vary and do not override FDA's authority over the product itself.
• For autism specifically, no stem cell or exosome product has completed the Phase 2 or Phase 3 trials that would be required to support FDA approval — meaning any Right to Try access in this space remains, by definition, investigational.

Frequently Asked Questions